IMGN853-0421/GOG-3078: Randomized, Multicenter, Open-label, Phase 3 study of Mirvetuximab Soravtansine in Combination with Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients with FRa-positive Recurrent Platinum-sensitive Epithelial o

Grants and Contracts Details

StatusActive
Effective start/end date8/30/23 → 8/30/25

Funding

  • ImmunoGen Inc: $23,431.00